Inside India's new cervical cancer test that detects dangerous HPV strains in minutes

India has launched its first homegrown HPV DNA test, Truenat HPV-HR Plus, developed by Molbio Diagnostics. The test detects eight high-risk HPV strains responsible for most cervical cancer cases, offering faster and more accurate screening than traditional methods like Pap smears. A study published in the *International Journal of Cancer* confirmed it meets WHO standards set by the International Agency for Research on Cancer (IARC), validated by Indian and international institutions including AIIMS New Delhi, ICMR, and IARC in France. The test uses automated molecular technology to identify viral DNA, reducing human error and unnecessary follow-ups. Unlike conventional tests covering 14 strains, this eight-valent version focuses on the most dangerous types, improving efficiency and affordability for low-resource settings. Researchers found it highly accurate in detecting precancerous lesions, aligning with WHO’s recommendation to prioritize HPV DNA testing over Pap smears. The validation comes as India expands HPV vaccination and screening programs for women over 30. Since the Truenat platform is already widely used for infectious disease diagnostics, the HPV test can be easily integrated into existing healthcare systems. Experts believe this affordable, locally developed solution will enhance screening in underserved regions, aiding India’s goal to eliminate cervical cancer as a public health problem. Cervical cancer remains a leading cause of cancer deaths among Indian women. The new test’s specificity and speed could reduce costs and anxiety by avoiding unnecessary procedures for temporary infections. Its deployment aligns with global efforts to improve early detection and treatment, particularly in areas with limited healthcare access.